Project Grant R01AI200929
Award Date 9/3/26
Completion Date 8/31/31
Dollars Obligated $443K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
West Lafayette, IN, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded Purdue University $239,023 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop covalent phosphatidylinositol 4-kinase (PI4K) inhibitors targeting malaria parasites. The project executes hit-to-lead optimization of high-priority molecular scaffolds against Plasmodium species that inhibit...
- The National Institute of Allergy and Infectious Diseases awarded Purdue University $248,814 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for hit-to-lead drug development targeting Acanthamoeba keratitis. Purdue will optimize a novel chemical class of benzoxazepinoindazole inhibitors to develop potent drug candidates for treating Acanthamoeba keratitis, a difficult-to-resolve eye infection caused by free-living amoeba exposure during improper...
- The National Institute of Allergy and Infectious Diseases awarded Purdue University $229,127 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop CDC14 phosphatase inhibitors as novel antifungal agents. The project addresses invasive fungal diseases, which contribute to approximately 3.8 million deaths annually, particularly among immunocompromised populations. The work optimizes chemical compounds that selectively inhibit CDC14, a fungal protein...
- The National Institute of Allergy and Infectious Diseases awarded Purdue University $498,154 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research into signaling mechanisms governing chimeric antigen receptor T cell activation. The research addresses a critical gap in understanding how CAR T cells recognize and eliminate target cells while avoiding off-target activation and collateral damage. CAR T cells express artificial receptors...
- The National Institute of Allergy and Infectious Diseases awarded Oregon State University $495,688 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct mechanistic and structural studies of ureido bond formation in the biosynthesis of three families of bioactive bacterial natural products: anabaenopeptins, syringolins, and muramycins. The work dissects how bacteria assemble these ureido-containing molecules through non-ribosomal peptide...
- Federal Project Grant Award Summary Purdue University received a $406,260 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 1, 2025, through June 30, 2027. The award supports the development of a novel computational framework for B-cell epitope prediction based on immune-induced selection signatures. The project will deliver two primary products: (1) a comprehensive antigen...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $474,363.00 to Rowan University to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The goal is to create new peptide molecules that mimic daptomycin's key mechanisms of action, such as calcium binding and lipid membrane disruption, while improving resistance to...
- The National Institute of Allergy and Infectious Diseases awarded The University Corporation $147,500 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a multi-scale study of antimicrobial peptide action in non-standard bacterial growth states. The project addresses how antimicrobial peptides (AMPs)—immune-derived molecules that kill bacteria by disrupting membranes and modulate host immune responses—perform under physiologically relevant...
- The National Institute of Allergy and Infectious Diseases awarded the University of Notre Dame DU Lac $709,532 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct systematic research into the cytoplasmic pathway for peptidoglycan recycling in Pseudomonas aeruginosa, an antibiotic-resistant gram-negative bacterial pathogen responsible for recurrent lung infections in cystic fibrosis patients. The work addresses two specific aims. The first...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $148,614 to Massachusetts Institute of Technology on January 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop glycopolymers designed to enhance interactions between immune cells and pathogenic bacteria, creating "cellular glues" that leverage the body's innate immune mechanisms as an alternative to...